Close Menu

NEW YORK (GenomeWeb) – Interpace Diagnostics reported yesterday a 32 percent rise in third quarter revenues, in part due to an increase in test and collection volume for its thyroid cancer diagnostics.

For the three-month period ended Sept. 30, Interpace's revenues climbed to $3.3 million from $2.5 million the year before, due in part to higher test and collection volume for the company's ThyraMir and ThyraGenX thyroid cancer assays. Also driving revenues was an increase in the amounts collected based on Medicare coverage for ThyraMir.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Apr
23
Sponsored by
N-of-One

In 2016, the Association for Molecular Pathology (AMP), in partnership with the College of American Pathologists (CAP) and American College of Molecular Genetics (ACMG), launched a set of guidelines meant to set industry standards for reporting of molecular diagnostic test results in oncology, using a tier-based system and defined levels of evidence. 

Apr
24
Sponsored by
Biocrates

This webinar will provide a wide-ranging overview of the promise for metabolomics in studying human health and disease, as well as its potential for integration with other -omics disciplines.

Apr
30
Sponsored by
Lexogen

This webinar will discuss novel long-read transcript sequencing (LRTseq) methods for transcriptome annotation that could increase the efficiency and accuracy of future sequencing projects.

May
08
Sponsored by
Sysmex Inostics

This webinar will present recent evidence that demonstrates how incorporating circulating tumor DNA (ctDNA) assessments into real-world patient management can influence patient care decisions, alter radiographic interpretations, and impact clinical outcomes.